Kornimate/medical-research-clean huggingface dataset:
video assisted thoracoscopic surgery (vats) - surgical pleurodesis vs tube drainage in management of malignant pleural effusion (mpe)

Conditions: Malignant Pleural Effusion; Thoracic Cancer

Summary: malignant pleural effusion (mpe) is considered to be a common presentation at malignant tumors representing 15% of all cancer cases. it carries a burden on our patients with dyspnea being the most common symptom in most of cases. management of symptomatic malignant pleural effusion remains to be a point of debate. data available from literature shows conflicting results lacking high quality evidence which necsscitates further research work. options differs to include chemical pleurodesis using medical or surgical talc poudrage or slurry. surgical intervention with abrasion pleurodesis or pleurectomy using vats approach has been used in many studies. using indwelling pleural catheters (ipcs) has also proved comparable efficacy at many clinical trials. in this study we want to help answering this question so that we can add to the current knowledge aiming to offer the best care for those patients


Eligibility criteria:
inclusion criteria: * 1-patients with symptomatic malignant pleural effusion. 2- symptomatic patients with shortness of breath. 3-lung can be fully expanded. exclusion criteria: 1. patients with non symptomatic malignant pleural effusion 2. pleural symphysis with no potentiality for re-expansion 3. patients managed surgically through open thoracotomy. 4. pleural effusion due to causes other than malignancy 5. loculated malignant effusion judged by chest ultrasound 6. trapped lung due to malignant pleural effusion assessed by multislice ct chest., 7. .refusal to share the research project and not to sign the consent.

Keywords: malignant pleural effusion vats pleurx abrasion
fear among dentists during covid-19 pandemic

Conditions: COVID

Summary: this study aimed to evaluate the anxiety and fear of infection between dentists working during the present corona virus disease 2019 (covid-19) pandemic and to explore dentist's knowledge about various practice modifications and guidelines to fight the novel corona virus

the spread of corona virus (covid-19) has posed significant challenges for dentistry and medicine, and dental and medical schools, in all affected countries. the speed of reaction and type of response to this disease around the world have been very variable according to differing healthcare systems, economies and political ideologies

Eligibility criteria:
inclusion criteria: * dentist having bachelor of dentistry or equivalent degree exclusion criteria: * paramedical staff and dental students

Keywords: fear practice modification covid-19 epidemic
outcomes of patients with heart failure hospitalized in an internal medicine unit

Conditions: Heart Failure

Summary: in 2018, the investigators evaluated the treatment of 236 patients with heart failure (with preserved or reduced ejection fraction) before and after hospitalization in our internal medicine unit (from 2016 to 2017). the investigators showed that patients, mainly elderly women with comorbidities, often had suboptimal heart failure treatment without an identified cause. the investigators tried, whenever possible, to optimize treatment before hospital discharge. our objective is now to analyze the 4-year outcome of these patients, including re-hospitalization for heart failure or death.


Eligibility criteria:
inclusion criteria: - patients hospitalized in our internal medecine unit for acute heart failure or for another cause but with known chronic heart failure exclusion criteria: - hemodilaysis, end stage kidney disease, heart failure cause by anuria, heart transplantation

Keywords: outcomes internal medecine heart failure treatment heart failure guidelines quality of life
the efficacy of lymph node dissection for stage iiicr of cervical cancer(cqgog0103)

Conditions: Cervical Cancer

Summary: this is an national, prospective, multicenter and randomized clinical study designed to determine if patients with stage iiicr of cervical cancer have longer pfs and/or os with lymph node dissection before ccrt when compared to ccrt.

all eligible patients will be equally randomized between the 2 following treatment groups (stratified factors: whether para-aortic lymph nodes were image-positive): standard treatment group: standard chemoradiation (pelvic ebrt/extended-field ebrt + concurrent platinum-containing chemotherapy+brachytherapy). experimental group: open/minimally invasive pelvic and para-aortic lymph node dissection followed by chemoradiation. (level of lymph node dissection: at least the inferior mesenteric artery. chemoradiation will be performed postoperatively within 28 days.)

Eligibility criteria:
inclusion criteria: 1. histopathology: squamous cell carcinoma, adenocarcinoma, adeno-squamous cell carcinoma 2. cervical cancer stage iiicr (confirmed by ct/mri/pet/ct) and the short diameter of image-positive lymph node ≥15mm 3. ecog score 0\~1 4. expected survival over 6 months 5. the serum or urine pregnancy test must be negative within 7 days before enrollment for the women of childbearing age who should agree that contraception must be used during the trial 6. no surgical contraindication exclusion criteria: 1. activity or uncontrol severe infection 2. liver cirrhosis, decompensated liver disease 3. history of immune deficiency, including hiv positive or suffering from congenital immunodeficiency disease 4. chronic renal insufficiency or renal failure 5. has combined with other malignant tumor which diagnosed within 5 years and/or needed to be treated 6. myocardial infarction, severe arrhythmia and nyha (new york heart association)≥2 for congestive heart failure 7. a history of pelvic artery embolization 8. a history of pelvic radiotherapy 9. a history of partial hysterectomy or radical hysterectomy 10. a history of severe allergic reaction to platinum drugs 11. during the treatment for complications, the drugs which lead to serious liver and/or kidney function impairment need to be used, such as tuberculosis

Keywords: stage iiicr of cervical cancer lymph node dissection chemoradiation pfs
a study of the safety and effectiveness of topiramate on insulin sensitivity in overweight or obese patients with type 2 diabetes

Conditions: Obesity; Diabetes Mellitus, Type 2; Diabetes Mellitus, Adult-Onset

Summary: the purpose of this study is to investigate (1) the effect of topiramate on insulin sensitivity in overweight or obese patients with type 2 diabetes mellitus and (2) the safety of topiramate in type 2 diabetic patients. the study will also investigate the effect of topiramate on body weight, body fat, fat distribution, and metabolic control including both glucose and lipid levels.

topiramate is not approved for the treatment of obesity. this double-blind, placebo controlled study investigates the effect of topiramate on insulin sensitivity in overweight or obese patients with type 2 diabetes. after a screening phase, patients are randomized to receive either topiramate (96 milligrams\[mg\] twice daily) or placebo for 9 months in the double-blind phase. after 9 months, patients have the option to continue in the open-label phase and receive treatment with topiramate for 1 year. patients in the placebo group then receive topiramate with dosage increasing gradually to 96 mg twice daily, with the option of increasing to 256 mg twice daily. patients in the topiramate group continue with the maintenance dose received during the double-blind phase, with the option of increasing to 256 mg twice daily. assessments of effectiveness made monthly include insulin sensitivity, body composition (as measured by computed tomography \[ct\]), body weight and body mass index (bmi), waist and hip circumferences, fasting lipid profile, fasting glucose and hemoglobin type a1c (hba1c) levels, and blood pressure. safety evaluations, including incidence of adverse events, clinical laboratory results, vital signs, and electrocardiograms \[ecgs\]), are performed throughout the study. the study hypothesis is that topiramate will improve insulin sensitivity in type 2 diabetic patients and will be well tolerated. patients will be randomized to receive 192 mg/day (96mg twice daily) of topiramate, or placebo, per mouth for 9 months, with an option of topiramate treatment increasing to 256mg/day both groups during the extension period of 1 year.

Eligibility criteria:
inclusion criteria: * patients must have a history of type 2 diabetes for 6 months, treated either by diet alone or by sulfonylurea for at least 6 months * hemoglobin a1c between 6.5% and 10% * bmi between 27 and 50 * non-smokers * female patients must be postmenopausal for at least 1 year, surgically incapable of childbearing, practicing an acceptable method of contraception exclusion criteria: * unstable endocrine disease * significantly abnormal liver function or kidney functions * history of schizophrenia, major depressive disorder or eating disorder * history of epilepsy, kidney stones or substance (alcohol) abuse

Keywords: type 2 diabetes obesity insulin resistance body mass index hypertension hyperlipidemia sulfonylurea topiramate adult-onset diabetes mellitus metabolic syndrome
preemptive pregabalin in myringoplasty

Conditions: Post-operative Analgesia; CSOM - Chronic Suppurative Otitis Media

Summary: the aim of this study was to investigate the effect of preemptive pregabalin on post-operative pain reduction after myringoplasty.

patient were randomly assigned to one of two groups with 30 participants each by lottery method. pregabalin group received capsule pregabalin 150mg and placebo group were given vitamin b capsule 1 hour prior to surgery. all patients underwent endoscopic myringoplasty with tragal cartilage and perichondrium graft. surgical procedure was done under local anesthesia. 5ml of 2% xylocaine with 1:2,00,000 adrenalin was infiltrated in the four quadrants of external ear canal and on tragus. around 2cm incision was given on canal surface of tragus and around 2cm x 1.5cm cartilage- perichondrium graft was obtained. the skin was closed with 4/0 prolene interrupted suture. using rigid hopkins ii 0-degree endoscope (karl storz) with 4-millimeter diameter and 18 centimeters in length, margin of perforation was refreshed. gelatin sponge was kept in the middle ear and cartilage perichondrium graft placed. canal was then packed with gelatin soaked in ciprofloxacin ear drops followed by ribbon pack medicated with soframycin. small dressing was applied over it. post-operative pain severity was assessed with vas scale at 6, 12, 24, 48 hours. rescue analgesia is given with injection ketorolac (30mg iv) or tab flexon (ibuprofen 400mg + paracetamol 500mg) whenever the patient required.

Eligibility criteria:
inclusion criteria: * cases of chronic suppurative otitis media (csom) inactive planned for endoscopic myringoplasty under local anesthesia, * age \>= 18 years * either sex. exclusion criteria: * revision cases, * pregnancy or breastfeeding, * known or suspected sensitivity or contraindication to pregabalin, * patient using medication for chronic pain, * history of seizure disorder, * mental retardation.

Keywords: endoscopic ear surgery myringoplasty pregabalin preemptive analgesia
bevacizumab (avastin) and erlotinib (tarceva) in previously treated mesothelioma

Conditions: Mesothelioma

Summary: the purpose of this study is to determine whether the combination of the investigational drugs avastin and tarceva are effective in patients with mesothelioma who have previously been treated with chemotherapy.

each cycle of study treatment lasts 21 days. the patient will take erlotinib by mouth once daily. on day 1 of every cycle, the patient will receive bevacizumab intravenously over a 30-90 minute time period. ct scan(s), mri(s) and/or x-ray(s) of the cancer site will be performed every 6 weeks (2 cycles) to assess the extent of the response to treatment. bloodwork will be performed before the first dose of erlotinib and bevacizumab at cycle 1, cycle 2, cycle 3, and at the end of treatment. at the completion of the treatment a physical exam, vital signs, blood tests, urine tests and standard radiologic testing will be performed. the duration of study depends upon how the patients' mesothelioma responds to treatment as well as how well the patient tolerates the medication.

Eligibility criteria:
inclusion criteria: * mesothelioma that has been previously treated with at least one chemotherapy regimen * 18 years of age or older * must at least be able to walk and capable of taking care of oneself although unable to carry out work activities * four or more weeks since last major surgery * four or more weeks since last radiation therapy * three or more weeks since last chemotherapy * life expectancy of 12 weeks or more * blood tests that show kidneys, liver and bone marrow to be working adequately * able to comply with study and/or follow-up procedures exclusion criteria: * prior exposure to tarceva (osi-774, erlotinib), trastuzumab, zd1839 or c225 * receiving anticoagulation medication other than low dose coumadin * clinically significant heart disease such as uncontrolled hypertension, previous heart attack within past 12 months, uneven heartbeat, etc. * history of central nervous system disease such as seizures not controlled with standard medical therapy, brain metastases or history of stroke * major surgery within 28 days of screening * daily treatment with aspirin or anti-inflammatory medications * pregnant or lactating (pertaining to women only) * serious or nonhealing wound, ulcer or bone fracture * difficulty swallowing * a disease or disorder that interferes with ability to digest and absorb food * history of coughing up more than 1/4 teaspoon of blood * a medical condition that could make it unsafe for patient to participate in this study

Keywords: mesothelioma avastin bevacizumab tarceva osi-774 erlotinib
a novel electrolyzed water spray treatment for the discomfort or itching of patients with scalp

Conditions: Scalp Dermatoses

Summary: the purpose of this study is to test whether the reduction of the discomfort or itching with the scalp of patients by use of the novel electrolyzed water spray will produce improvement in the condition of the scalp.

in this study, water inculding tap water,pure water and salt water, and an apparatus for producing electrolyzed water (https://www.deposon.com.cn; https://www.deposon.com）were used to generate an electrolyzed water mist spray or spray. this instantly generated electrolyzed water mist spray or spray has oxidation-reduction potential (orp) ≥1200mv,and contains non-specific total oxidation capacity which equals to 0.28±0.10ppm,0.06±0.04ppm and 3.92±0.39ppm of desolved ozone. this instantly generated electrolyzed water mist spray or spray does not release detectable ≥0.1mg/m3 of gaseous ozone. this instantly generated electrolyzed water mist spray or spray has ph 8.4±0.4 and releases negative air ion.the apparatus for producing electrolyzed water has a positive electrode which is covered by a conductive diamond material (patent# cn215308550u). this is an open-label, single-arm and before and after treatment comparison study. in this study, this novel electrolyzed water device and the water spray are used to treat scalp itching. the reduction in the scalp of discomfort or itching evaluation and adverse event assessments will be performed at each visit. safety analysis will be assessed based on the reports of adverse events during the study.

Eligibility criteria:
inclusion criteria: * the patients with scalp discomfort or itching exclusion criteria: * severe scalp discomfort or itching; 80 years or elder

Keywords: electrolyzed water device hydroxyl radical tap water spray scalp discomfort scalp itching
efficacy/safety of ecraprost in lipid emulsion for treatment of critical leg ischemia due to peripheral arterial disease

Conditions: Peripheral Vascular Disease

Summary: ecraprost in lipid emulsion is being developed for the treatment of critical leg ischemia (cli), which is the most severe form of peripheral arterial disease (pad); this trial is designed to assess the efficacy and safety of the drug in the treatment of cli.


Eligibility criteria:
inclusion criteria: * critical leg ischemia (cli) defined as distal extremity pain at rest, or peripheral ischemic ulcer(s), with severe hemodynamic impairment as diagnosed by ankle systolic pressure, toe systolic pressure or tcpo2 * subjects will already be scheduled to receive a revascularization procedure (e.g., by-pass graft, endovascular procedure, etc.) involving a distal target artery below the knee joint (e.g., below the knee joint popliteal, anterior/posterior tibial, peroneal, plantar, pedal, etc.) as part of their normal standard of care. exclusion criteria: * subjects with a previous major amputation (at or above ankle) * subjects with end stage renal disease (esrd) defined as significant renal dysfunction evidenced by estimated creatinine clearance of \< 20 cc/min, or receiving chronic hemodialysis therapy.

Keywords: ecraprost in lipid emulsion cli peripheral, vascular amputation angioplasty by-pass critical limb ischemia due to peripheral arterial disease
predictive value of infarction volume on hemorrhagic transformation in ischemic stroke/tia with non-valve atrial fibrillation(nvaf) patients using rivaroxaban

Conditions: Cerebrovascular Stroke; Intracranial Hemorrhages; Anticoagulant; Matrix Metalloproteinases

Summary: this study was aimed at patients with newly diagnosed stroke / tia associated with nonvalvular atrial fibrillation. we will observe the effect of early using rivaroxaban anticoagulation on hemorrhagic transformation, and explore the predictive value of multi-mode mri infarct volume / mmp-9 on hemorrhagic transformation after anticoagulation therapy.


Eligibility criteria:
inclusion criteria: 1. male or female, age≥18; 2. were newly diagnosed asischemic stroke/tia concomitant nvaf; 3. prescribedand accept rivaroxaban; 4. sign thewritten informed consent. exclusion criteria: 1. renal impairment (crcl\<15 ml/min) or severe hepatic impairment. 2. significant hemorrhagic transformation (parenchymal hematoma type i or type ii by the ecass definition). 3. stroke or tia caused by large artery atherosclerosis 4. planned major surgery or invasive intervention 5. active internal bleeding 6. malignancy or other serious medical conditions with a life expectancy \<6 months 7. allergery to rivaroxaban 8. pregnancy or breast-feeding
evaluation of the latella™ knee implant system for medial osteoarthritis pain reduction

Conditions: Osteoarthritis

Summary: the objective of the latella-us study is to demonstrate the safety and efficacy of the latella knee implant system for the reduction of medial osteoarthritis pain.


Eligibility criteria:
inclusion criteria: * history of pain due to medial osteoarthritis * qualifying baseline pain scores * kellgren-lawrence grades 2-3 exclusion criteria: * osteoporosis * rheumatoid arthritis * joint instability * metal ion allergy * permanent implant in or around the knee joint * prior anterior cruciate ligament reconstruction
prefem: "what happens to the vaginal microbiota when a bv infection is treated with metronidazole?"

Conditions: Bacterial Vaginosis

Summary: the study will assess vaginal microbiota levels before and after antibiotic treatment in females infected with bacterial vaginosis (bv).

this method validation study will endeavour to obtain evidence for: * recruitment methodology effectiveness * the usefulness of the "canestest" test as a screening tool * the time required for the vaginal microbiota (particularly lactobacillus count) to return to normal after treatment of bv infection with metronidazole. * the time required for the nugent score to return to normal after treatment of bv infection with metronidazole.

Eligibility criteria:
inclusion criteria: * signed informed consent * female gender * over 18 years of age * have a high probability for compliance with and completion of the study exclusion criteria: * hypersensitivity to metronidazole --only applies to group 2. * post-menopausal defined as at least 12 consecutive months without menstruation * treatment of bv in last 4 weeks * clinically significant menstrual irregularities * suspected presence of stds or other vaginal infection * pregnancy * breast feeding * participation in other clinical studies which could influence genitourinary tract microbiota * substance abuse * investigator believes that the participant may be uncooperative and/or noncompliant and should therefore not participate in the study
study to evaluate the safety and pharmacokinetics of medi9090 in subjects with advanced solid tumors

Conditions: Advanced Solid Tumors

Summary: this is an open-label, study of medi9090 to evaluate the safety, tolerability, pk, immunogenicity, and antitumor activity of medi9090 in adult subjects with advanced solid tumors.


Eligibility criteria:
inclusion criteria: * male and female subjects * 18 years and older * must have histologic documentation of advanced solid tumors * must have received and have progressed, are refractory or, intolerant to standard therapy and must not have a curative therapy option exclusion criteria: * concurrent enrollment in another clinical study * prior participation in clinical studies that include durvalumab alone or in combination * concurrent chemotherapy, immunotherapy, biologic, or hormonal therapy for cancer treatment

Keywords: advanced solid tumor immunotherapy medi9090 medi4736 durvalumab